DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Dan Lyons - 1 Janus Henderson - 1 John Newman - 1 Canaccord Genuity - 1 Janus - 1 Lyons - 1 Bristol Myers Squibb - 1 Karuna - 1
Top related locs:
ImmunoGen
Top related orgs:
Drug - 1 Federal - 1 Bristol Myers - 1 Karuna Therapeutics - 1 CART - 1 Bristol Myers Squibb - 1 Cerevel Therapeutics - 1 Securities and Exchange Commission - 1

Search resuls for: "resmetirom"


3 mentions found


☆ Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
  + stars: | 2023-12-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com   time to read: +8 min
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. "We expect this environment to continue but look forward to the prospect of lower interest rates in 2024." When that happens, Canaccord Genuity said to expect a "strong rally across the biotech sector rewarding innovative, but riskier assets." Analysts have said the rich price reflects the opportunity for ImmunoGen's Elahere cancer treatment , which has quickly established itself as the standard of care for types of ovarian cancer. 'Oversold and cheap' In a research note Friday, Jefferies analyst Michael Yee said "a significant short squeeze" was helping biotech stocks in the fourth quarter.
Persons: Dan Lyons, Janus Henderson, John Newman, Canaccord Genuity, Janus, Lyons, Bristol Myers Squibb, Karuna, AstraZeneca, Eli Lilly, AbbVie, Jonathan Miller, Miller, bode, Jonathan Krinsky, Krinsky, BTIG's, Jefferies, Michael Yee, Yee, NASH, Madrigal, we're, David Risinger, — CNBC's Michael Bloom Organizations: Drug, Federal, Bristol Myers, Karuna Therapeutics, CART, Bristol Myers Squibb, Cerevel Therapeutics, Securities and Exchange Commission, pharma, P Biotech, Nasdaq Biotech, Apogee Therapeutics, Madrigal Pharmaceuticals, Madrigal, resmetirom, Vertex Pharmaceuticals, Leerink Partners Locations: ImmunoGen
☆ Madrigal NASH drug meets goals in much-awaited trial, shares surge
  + stars: | 2022-12-19 | by ( ) www.reuters.com   time to read: +1 min
Dec 19 (Reuters) - Madrigal Pharmaceuticals' (MDGL.O) experimental drug for fatty liver disease met both of the main goals in a highly anticipated late-stage study, it said on Monday, sending the company's shares soaring over 200%. The positive data sets the stage for the drug, resmetirom, to become the first approved treatment for NASH, or nonalcoholic steatohepatitis, a disease that affects about 5% of adults in the United States. Data from the trial shows a lower 80 milligram dose helped 26% of patients reach NASH resolution, compared to 30% for a higher 100 milligram dose, and 10% for placebo. NASH is a form of nonalcoholic fatty liver disease, characterized by the organ developing fibrosis or scarring, which can progress to cirrhosis and liver failure. The company plans to file a marketing application seeking accelerated approval for the drug in the first half of 2023.
☆ A tiny biotech's experimental treatment for a silent disease that strikes millions just cleared a key hurdle and the stock is up more than 200%
  + stars: | 2022-12-19 | by ( Sarah Braner | ) www.businessinsider.com   time to read: +2 min
Madrigal Pharmaceuticals reported positive results in its phase 3 trial for a drug to treat NASH. NASH is a serious liver condition that does not have an FDA-approved treatment. Many people don't even know they have it, which is why some people call it a "silent" disease. In a trial of more than 950 patients, 26% of patients taking 80mg and 30% of patients taking 100mg of the drug showed that NASH activity like swelling had been reduced. Pharma hasn't found a way to treat NASH yetThe pharma industry has been watching NASH for a while.
0 next >>
Total: 3